Mirdametinib Responses Deepen Through Year 4 in ReNeu Long-Term Data
Long-term ReNeu data show mirdametinib confirmed ORR of 46.6% in adults and 55.4% in children, with deepening tumor shrinkage and waning adverse effects through year 4.
Topic
Reneu Trial
Topic